跳转至内容
Merck
所有图片(1)

文件

1288463

USP

吉西他滨

United States Pharmacopeia (USP) Reference Standard

别名:

2';-脱氧-2',2'-二氟胞苷; dFDC, Gemzar (Lilly), LY-188011, dFdC, dFdCyd

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C9H11F2N3O4 · HCl
CAS号:
122111-03-9
分子量:
299.66
MDL號碼:
MFCD01735988
分類程式碼代碼:
41116107
PubChem物質ID:
329749929
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

gemcitabine

製造商／商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

Cl.NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F

InChI

1S/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H/t4-,6-,7-;/m1./s1

InChI 密鑰

OKKDEIYWILRZIA-OSZBKLCCSA-N

基因資訊

human ... POLA1(5422) , POLA2(23649) , POLD1(5424) , POLD2(5425) , POLD3(10714) , POLD4(57804) , POLE(5426) , POLE2(5427) , POLE3(54107) , PRIM1(5557) , PRIM2(5558) , RRM1(6240) , RRM2(6241) , RRM2B(50484)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般說明

本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息小册子，均由药典颁发机构制定和发布。

如需进一步的信息和支持，请访问药典发布网站。

應用

本品为美国药典参考标准品(USP Reference Standard)，用于专门的质量试验和分析。
也用于制备LC-UV法检测和杂质分析用标准溶液，用于下列美国药典(USP)专论中的药物分析：
  • 盐酸吉西他滨
  • 注射用吉西他滨

生化／生理作用

吉西他滨是诊所和研究实验室中广泛使用的抗肿瘤药物。它是一种抗肿瘤药和抗代谢药。

分析報告

这些产品仅供测试和化验使用。它们不适用于人类或动物，也不能用于诊断、治疗或治愈任何类型的疾病。

其他說明

可能适用相应的销售限制。

象形圖

Health hazard
GHS08

訊號詞

Danger

危險聲明

H360

危險分類

Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Katsumi Fukamachi et al.
PloS one, 9(10), e111481-e111481 (2014-10-28)
Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease, which is usually diagnosed in an advanced stage. We have established transgenic rats carrying a mutated K-ras gene controlled by Cre/loxP activation. The animals develop PDA which is histopathologically similar to
Erez Hasnis et al.
Neoplasia (New York, N.Y.), 16(6), 501-510 (2014-06-25)
Weekly gemcitabine therapy is the major treatment offered for patients with pancreatic adenocarcinoma cancer; however, relative resistance of tumor cells to chemotherapy, rapid regrowth, and metastasis are the main causes of death within a year. Recently, the daily continuous administration
Jeffrey R Infante et al.
Investigational new drugs, 33(2), 432-439 (2015-02-03)
Background This Phase 1b study aimed to determine the recommended Phase 2 dose of LY2334737, an oral pro-drug of gemcitabine, in combination with capecitabine, an oral pro-drug of 5-fluorouracil, in patients with advanced solid tumors. In addition, pharmacokinetics (PK) and
Minggen Hu et al.
Surgical endoscopy, 28(9), 2584-2591 (2014-04-08)
Laparoscopic distal splenopancreatectomy (DSP) is an effective and safe surgical modality for treating benign and borderline distal pancreatic tumors, but rarely for pancreatic cancer. This study aimed to examine the feasibility, effectiveness, and safety of laparoscopic versus laparotomic DSP in
Simone Limmer et al.
Pharmaceutical research, 31(9), 2276-2286 (2014-03-07)
The pyrimidine analogue gemcitabine (dFdC) is frequently used in the treatment of patients with solid tumors. However, after i.v. application dFdC is rapidly inactivated by metabolization. Here, the potential of thermosensitive liposomes based on 1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol (DPPG2-TSL) were investigated as carrier
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门